TABLE 2.
Specificity of IgM antibodies for OspC variantsa
| Serum ID | A | B | C | D | E | F | G | H | I | J | K | L | M | OspC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | − | + | + | + | + | + | + | − | − | − | − | − | n.d. | + |
| 2 | − | + | + | + | + | + | + | − | n.d. | n.d. | n.d. | n.d. | n.d. | + |
| 3 | − | + | + | + | + | + | + | − | − | − | − | − | − | + |
| 4 | − | + | + | + | + | + | + | − | − | − | − | − | n.d. | + |
| 5 | − | + | + | + | + | + | + | − | − | + | − | +/− | − | + |
| 6 | − | + | + | + | + | + | + | − | − | + | − | + | − | + |
| 7 | − | + | + | + | + | + | + | − | − | − | − | + | − | + |
| 8 | − | + | + | + | + | + | + | − | − | − | − | − | − | + |
| 9 | − | + | + | + | + | + | + | − | − | +/− | − | + | +/− | + |
| 10 | − | +/− | +/− | + | + | + | + | − | − | − | − | − | n.d. | + |
| 11 | − | + | + | + | + | + | + | − | − | − | − | − | n.d. | + |
| 12 | − | + | + | + | + | + | + | − | − | +/− | − | + | +/− | + |
| 13 | − | + | + | + | + | + | + | − | − | + | − | +/− | +/− | + |
| 14 | − | + | + | + | + | + | + | − | − | − | − | − | +/− | + |
| 15 | − | + | + | + | + | + | + | − | + | + | + | − | − | + |
a(−) no reaction; (+) reaction; (+/−) weak reaction; n.d., not determined.